Prospective Observational Study on Plerixafor After Chemotherapy
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Plerixafor is a new CXCR4 inhibitor that is able to improve peripheral blood stem cell (PBSC)
mobilization when combined with granulocyte-colony-stimulating factor (G-CSF). The 'on
demand' use of plerixafor at the hematopoietic recovery after chemotherapy + G-CSF may be
more efficient and cost-effective, but the timing of administration and criteria for patient
selection are still under investigation. We collected the data of lymphoma and myeloma
patients treated with plerixafor at the hematopoietic recovery after chemotherapy + G-CSF.
The decision of adding plerixafor was based on PB CD34+ cells at the time of hematopoietic
recovery after chemotherapy in patients at their first or subsequent attempt, according to
the attending physician choice. The primary endpoint was the assessment of the rate of
patients who were able to collect >=2 x 10^6 CD34+/kg.
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano